Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients

NCT01628393 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01628393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01628393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Lead sponsor
Celgene
Phase
Phase 2/3
Overall status
Completed
Start date
September 18, 2012
Completion date
May 11, 2016
Enrollment
258 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis